Journal article

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

MA Kamm, GR Lichtenstein, WJ Sandborn, S Schreiber, K Lees, K Barrett, R Joseph

GUT | BMJ PUBLISHING GROUP | Published : 2008

Abstract

AIM: Maintenance treatment in ulcerative colitis should be as convenient as possible, to increase the chance of compliance. MMX mesalazine is a once-daily, high-strength (1.2 g/tablet) formulation of 5-aminosalicylic acid. This study evaluated the safety and efficacy of MMX mesalazine dosed once or twice daily as maintenance therapy in patients with ulcerative colitis. METHODS: This multicentre, randomised, open-label trial enrolled patients with strictly defined clinical and endoscopic remission, immediately following an episode of mild to moderate ulcerative colitis. Patients were randomised to MMX mesalazine 2.4 g/day as a single (2x1.2 g tablet) or divided dose (1x1.2 g tablet twice dail..

View full abstract